

1. Cooper, C., G. Campion, and L.J. Melton, 3rd, *Hip fractures in the elderly: a world-wide projection*. *Osteoporos Int*, 1992. **2**(6): p. 285-9.
2. Malhotra, N. and A. Mithal, *Osteoporosis in Indians*. *Indian J Med Res*, 2008. **127**(3): p. 263-8.
3. Raisz, L.G., *Pathogenesis of osteoporosis: concepts, conflicts, and prospects*. *J Clin Invest*, 2005. **115**(12): p. 3318-25.
4. Riggs, B.L. and A.M. Parfitt, *Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling*. *J Bone Miner Res*, 2005. **20**(2): p. 177-84.
5. Nassar, A.H., et al., *Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era*. *Maturitas*, 2005. **52**(1): p. 18-25.
6. Canderelli, R., et al., *Benefits of hormone replacement therapy in postmenopausal women*. *J Am Acad Nurse Pract*, 2007. **19**(12): p. 635-41.
7. Lanham-New, S.A., *Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment*. *Proc Nutr Soc*, 2008. **67**(2): p. 163-76.
8. Cummings, S.R., et al., *Denosumab for prevention of fractures in postmenopausal women with osteoporosis*. *N Engl J Med*, 2009. **361**(8): p. 756-65.
9. Neer, R.M., et al., *Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis*. *N Engl J Med*, 2001. **344**(19): p. 1434-41.
10. Compston, J.E., *Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure*. *Bone*, 2007. **40**(6): p. 1447-52.
11. Hodsman, A.B., et al., *Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use*. *Endocr Rev*, 2005. **26**(5): p. 688-703.
12. Coxam, V., *[New advances in osteoporosis nutritional prevention]*. *Med Sci (Paris)*, 2005. **21**(3): p. 297-301.
13. Sharan, K., et al., *Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies*. *Curr Med Chem*, 2009. **16**(9): p. 1138-57.
14. Gurib-Fakim, A., *Medicinal plants: traditions of yesterday and drugs of tomorrow*. *Mol Aspects Med*, 2006. **27**(1): p. 1-93.
15. Maurya R, Singh G, Yadav PP. *Antiosteoporotic Agents from Natural Sources*. In: Rahman AU, editor. *Studies in Natural Product Chemistry, Bioactive Natural Products*. Elsevier, 2008: 517-548.
16. Gaur RD. *Flora of District Garhwal, North West Himalaya*; Trans Media: Srinagar, Garhwal, India, 1999. p 86.
17. Melton, L.J., 3rd, et al., *Perspective. How many women have osteoporosis?* *J Bone Miner Res*, 1992. **7**(9): p. 1005-10.

18. Khosla, S., S. Amin, and E. Orwoll, *Osteoporosis in men*. *Endocr Rev*, 2008. **29**(4): p. 441-64.
19. Van Pottelbergh, I., et al., *Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study*. *J Bone Miner Res*, 2003. **18**(2): p. 303-11.
20. Baron R. General principles of bone biology. In: Favus M, ed. *Primer on the metabolic bone diseases and disorders of mineral metabolism*. Philadelphia - New York: Lippincott-Raven publishers; 2003:1-8
21. Harada, S. and G.A. Rodan, *Control of osteoblast function and regulation of bone mass*. *Nature*, 2003. **423**(6937): p. 349-55.
22. Ducy, P., *Cbfa1: a molecular switch in osteoblast biology*. *Dev Dyn*, 2000. **219**(4): p. 461-71.
23. Nakashima, K., et al., *The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation*. *Cell*, 2002. **108**(1): p. 17-29.
24. Ziros, P.G., E.K. Basdra, and A.G. Papavassiliou, *Runx2: of bone and stretch*. *Int J Biochem Cell Biol*, 2008. **40**(9): p. 1659-63.
25. Stein, G.S., et al., *Transcriptional control of osteoblast growth and differentiation*. *Physiol Rev*, 1996. **76**(2): p. 593-629.
26. Aubin, J.E., *Advances in the osteoblast lineage*. *Biochem Cell Biol*, 1998. **76**(6): p. 899-910.
27. Datta, H.K., et al., *The cell biology of bone metabolism*. *J Clin Pathol*, 2008. **61**(5): p. 577-87.
28. Franz-Odenaal, T.A., B.K. Hall, and P.E. Witten, *Buried alive: how osteoblasts become osteocytes*. *Dev Dyn*, 2006. **235**(1): p. 176-90.
29. Feng, J.Q., L. Ye, and S. Schiavi, *Do osteocytes contribute to phosphate homeostasis?* *Curr Opin Nephrol Hypertens*, 2009. **18**(4): p. 285-91.
30. Sims, N.A. and J.H. Gooi, *Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption*. *Semin Cell Dev Biol*, 2008. **19**(5): p. 444-51.
31. Matsuo, K. and N. Irie, *Osteoclast-osteoblast communication*. *Arch Biochem Biophys*, 2008. **473**(2): p. 201-9.
32. Boyle, W.J., W.S. Simonet, and D.L. Lacey, *Osteoclast differentiation and activation*. *Nature*, 2003. **423**(6937): p. 337-42.
33. Quinn, J.M., et al., *A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro*. *Endocrinology*, 1998. **139**(10): p. 4424-7.
34. Halleen, J.M., et al., *Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption*. *J Bone Miner Res*, 2000. **15**(7): p. 1337-45.
35. Zhao, H. and F. Patrick Ross, *Mechanisms of osteoclastic secretion*. *Ann N Y Acad Sci*, 2007. **1116**: p. 238-44.
36. Williams, D.C. and C.A. Frolik, *Physiological and pharmacological regulation of biological calcification*. *Int Rev Cytol*, 1991. **126**: p. 195-292.
37. Seeman, E., *Periosteal bone formation--a neglected determinant of bone strength*. *N Engl J Med*, 2003. **349**(4): p. 320-3.
38. Whang, K., et al., *Engineering bone regeneration with bioabsorbable scaffolds with novel microarchitecture*. *Tissue Eng*, 1999. **5**(1): p. 35-51.

39. Parfitt, A.M., *Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone*. J Cell Biochem, 1994. 55(3): p. 273-86.
40. Marie, P.J., *Transcription factors controlling osteoblastogenesis*. Archives of Biochemistry and Biophysics, 2008. 473(2): p. 98-105.
41. Komori, T., *Regulation of skeletal development by the Runx family of transcription factors*. Journal of Cellular Biochemistry, 2005. 95(3): p. 445-453.
42. Celil, A.B., J.O. Hollinger, and P.G. Campbell, *Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling*. Journal of Cellular Biochemistry, 2005. 95(3): p. 518-528.
43. Huang, W., et al., *Signaling and transcriptional regulation in osteoblast commitment and differentiation*. Front Biosci, 2007. 12: p. 3068-92.
44. Yamaguchi, A., T. Komori, and T. Suda, *Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1*. Endocrine Reviews, 2000. 21(4): p. 393-411.
45. Ducy, P., *Cbfa1: a molecular switch in osteoblast biology*. Dev Dyn, 2000. 219(4): p. 461-471.
46. Nakashima, K., et al., *The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation*. Cell, 2002. 108(1): p. 17-29.
47. Lee, M.H., et al., *BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2*. Biochemical and Biophysical Research Communications, 2003. 309(3): p. 689-694.
48. McCabe, L.R., et al., *Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation*. Exp Cell Res, 1995. 218(1): p. 255-62.
49. Fujioka, S., et al., *NF-KB and AP-1 connection: Mechanism of NF-kappa B-Dependent regulation of AP-1 activity*. Molecular and Cellular Biology, 2004. 24(17): p. 7806-7819.
50. Strewler, G.J., *Local and systemic control of the osteoblast*. J Clin Investig, 2001. 107(3): p. 271-272.
51. Baylink, D.J., R.D. Finkelstein, and S. Mohan, *Growth factors to stimulate bone formation*. J Bone Miner Res, 1993. 8 Suppl 2: p. S565-572.
52. Westendorf, J.J., R.A. Kahler, and T.M. Schroeder, *Wnt signaling in osteoblasts and bone diseases*. Gene, 2004. 341: p. 19-39.
53. Kalajzic, I., et al., *Expression profile of osteoblast lineage at defined stages of differentiation*. Journal of Biological Chemistry, 2005. 280(26): p. 24618-24626.
54. Niu, T.H. and C.J. Rosen, *The insulin-like growth factor-I gene and osteoporosis: A critical appraisal*. Gene, 2005. 361: p. 38-56.
55. Canalis, E., A.N. Economides, and E. Gazzerro, *Bone morphogenetic proteins, their antagonists, and the skeleton*. Endocrine Reviews, 2003. 24(2): p. 218-235.
56. Miyazono, K., S. Maeda, and T. Imamura, *BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk*. Cytokine Growth Factor Rev, 2005. 16(3): p. 251-63.
57. Shi, Y. and J. Massague, *Mechanisms of TGF-beta signaling from cell membrane to the nucleus*. Cell, 2003. 113(6): p. 685-700.
58. Boden, S.D., et al., *Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies*. Spine, 2002. 27(23): p. 2662-73.

59. Mundy, G.R., *Nutritional modulators of bone remodeling during aging*. Am J Clin Nutr, 2006. 83(2): p. 427S-430S.
60. Stein, G.S. and J.B. Lian, *Molecular Mechanisms Mediating Proliferation Differentiation Interrelationships During Progressive Development of the Osteoblast Phenotype*. Endocrine Reviews, 1993. 14(4): p. 424-442.
61. Ash, P., J.F. Loutit, and K.M. Townsend, *Osteoclasts derived from haematopoietic stem cells*. Nature, 1980. 283(5748): p. 669-70.
62. Felix, R., M.G. Cecchini, and H. Fleisch, *Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse*. Endocrinology, 1990. 127(5): p. 2592-4.
63. Kodama, H., et al., *Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor*. J Exp Med, 1991. 173(1): p. 269-72.
64. Kodama, H., et al., *Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells*. J Exp Med, 1991. 173(5): p. 1291-4.
65. Simonet, W.S., et al., *Osteoprotegerin: a novel secreted protein involved in the regulation of bone density*. Cell, 1997. 89(2): p. 309-19.
66. Rodan, G.A. and T.J. Martin, *Role of osteoblasts in hormonal control of bone resorption--a hypothesis*. Calcif Tissue Int, 1981. 33(4): p. 349-51.
67. Sambrook, P. and C. Cooper, *Osteoporosis*. Lancet, 2006. 367(9527): p. 2010-2018.
68. Christiansen, C. and P. Riis, [*Consensus Development Conference. Prevention and treatment of osteoporosis*]. Nord Med, 1991. 106(5): p. 145-7.
69. Riggs, B.L., et al., *Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes*. J Clin Invest, 1982. 70(4): p. 716-23.
70. Anderson, J.J., *The important role of physical activity in skeletal development: how exercise may counter low calcium intake*. Am J Clin Nutr, 2000. 71(6): p. 1384-6.
71. Minelli, C., et al., *Benefits and harms associated with hormone replacement therapy: clinical decision analysis*. Bmj, 2004. 328(7436): p. 371.
72. Anthony, M., J.K. Williams, and B.K. Dunn, *What would be the properties of an ideal SERM?* Ann N Y Acad Sci, 2001. 949: p. 261-78.
73. Clemett, D. and C.M. Spencer, *Raloxifene: a review of its use in postmenopausal osteoporosis*. Drugs, 2000. 60(2): p. 379-411.
74. Grady, D., et al., *Hormone therapy to prevent disease and prolong life in postmenopausal women*. Ann Intern Med, 1992. 117(12): p. 1016-37.
75. Rodan, G.A., *Bone mass homeostasis and bisphosphonate action*. Bone, 1997. 20(1): p. 1-4.
76. Sharpe, M., S. Noble, and C.M. Spencer, *Alendronate: an update of its use in osteoporosis*. Drugs, 2001. 61(7): p. 999-1039.
77. Chesnut, C.H., 3rd, et al., *A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group*. Am J Med, 2000. 109(4): p. 267-76.
78. Crandall, C., *Parathyroid hormone for treatment of osteoporosis*. Arch Intern Med, 2002. 162(20): p. 2297-309.
79. Food and Drug Administration. *Blackbox warning: Teriparatide injection*. Available at: [www.fda.gov](http://www.fda.gov). Accessed August 25, 2003.

80. Henriksen, D.B., et al., *Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women*. Bone, 2007. 40(3): p. 723-9.
81. Vasiljeva, O., et al., *Emerging roles of cysteine cathepsins in disease and their potential as drug targets*. Curr Pharm Des, 2007. 13(4): p. 387-403.
82. Glass, D.A., 2nd and G. Karsenty, *In vivo analysis of Wnt signaling in bone*. Endocrinology, 2007. 148(6): p. 2630-4.
83. Krishnan, V., H.U. Bryant, and O.A. Macdougald, *Regulation of bone mass by Wnt signaling*. J Clin Invest, 2006. 116(5): p. 1202-9.
84. Baron, R. and G. Rawadi, *Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton*. Endocrinology, 2007. 148(6): p. 2635-43.
85. Somekawa, Y., et al., *Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women*. Obstet Gynecol, 2001. 97(1): p. 109-15.
86. Mei, J., S.S. Yeung, and A.W. Kung, *High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women*. J Clin Endocrinol Metab, 2001. 86(11): p. 5217-21.
87. Kritz-Silverstein, D. and D.L. Goodman-Gruen, *Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women*. J Womens Health Gend Based Med, 2002. 11(1): p. 69-78.
88. Setchell, K.D., *Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones*. Am J Clin Nutr, 1998. 68(6 Suppl): p. 1333S-1346S.
89. De Wilde, A., et al., *A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets*. J Cell Physiol, 2004. 200(2): p. 253-62.
90. Kuiper, G.G., et al., *Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta*. Endocrinology, 1998. 139(10): p. 4252-63.
91. Pino, A.M., et al., *Dietary isoflavones affect sex hormone-binding globulin levels in postmenopausal women*. J Clin Endocrinol Metab, 2000. 85(8): p. 2797-800.
92. Adlercreutz, H. and W. Mazur, *Phyto-oestrogens and Western diseases*. Ann Med, 1997. 29(2): p. 95-120.
93. Ciolino, H.P., P.J. Daschner, and G.C. Yeh, *Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially*. Biochem J, 1999. 340 ( Pt 3): p. 715-22.
94. Van der Heiden, E., et al., *Food flavonoid aryl hydrocarbon receptor-mediated agonistic/antagonistic/synergic activities in human and rat reporter gene assays*. Anal Chim Acta, 2009. 637(1-2): p. 337-45.
95. Ryan, E.P., et al., *Environmental toxicants may modulate osteoblast differentiation by a mechanism involving the aryl hydrocarbon receptor*. J Bone Miner Res, 2007. 22(10): p. 1571-80.
96. Maurya R, Singh G, Yadav PP. *Antiosteoporotic Agents from Natural Sources*. In: Rahman AU, editor. Studies in Natural Product Chemistry, Bioactive Natural Products. Elsevier, 2008: 517-548.
97. Gaur RD. *Flora of District Garhwal, North West Himalaya*; Trans Media: Srinagar, Garhwal, India, 1999. p 86.
98. Rawat, P., et al., *Ulmosides A and B: Flavonoid 6-C-glycosides from Ulmus wallichiana, stimulating osteoblast differentiation assessed by alkaline phosphatase*. Bioorganic & Medicinal Chemistry Letters. In Press, Corrected Proof.

99. Maurya R, Rawat P, Sharan K, Siddiqui JA, Swarnkar G, Mishra G, Manickavasagam L, Jain GK, Arya KR, Chattopadhyay N. PCT Patent no. PCT/IN2009/000146.
100. Kelsey, J.L., *Risk factors for osteoporosis and associated fractures*. Public Health Rep, 1989. 104 **Suppl**: p. 14-20.
101. Seeman, E., C. Tsalamandris, and C. Formica, *Peak bone mass, a growing problem?* Int J Fertil Menopausal Stud, 1993. 38 **Suppl 2**: p. 77-82.
102. Bhargavan, B., et al., *Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling*. J Cell Biochem, 2009.
103. Pastoureau, P., A. Chomel, and J. Bonnet, *Specific evaluation of localized bone mass and bone loss in the rat using dual-energy X-ray absorptiometry subregional analysis*. Osteoporos Int, 1995. 5(3): p. 143-9.
104. Trivedi, R., et al., *Effects of Egb 761 on bone mineral density, bone microstructure, and osteoblast function: Possible roles of quercetin and kaempferol*. Mol Cell Endocrinol, 2009. 302(1): p. 86-91.
105. Trivedi, R., et al., *Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats*. Mol Cell Endocrinol, 2008. 289(1-2): p. 85-93.
106. Maniatopoulos, C., J. Sodek, and A.H. Melcher, *Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats*. Cell Tissue Res, 1988. 254(2): p. 317-30.
107. Frost, H.M. and W.S. Jee, *On the rat model of human osteopenias and osteoporoses*. Bone Miner, 1992. 18(3): p. 227-36.
108. Kalu, D.N., *The ovariectomized rat model of postmenopausal bone loss*. Bone Miner, 1991. 15(3): p. 175-91.
109. Lin, Y.C., et al., *Peak spine and femoral neck bone mass in young women*. Bone, 2003. 32(5): p. 546-53.
110. Orwoll, E.S., J.K. Belknap, and R.F. Klein, *Gender specificity in the genetic determinants of peak bone mass*. J Bone Miner Res, 2001. 16(11): p. 1962-71.
111. Comelekoglu, U., et al., *Biomechanical evaluation in osteoporosis: ovariectomized rat model*. Clin Rheumatol, 2007. 26(3): p. 380-4.
112. Reagan-Shaw, S., M. Nihal, and N. Ahmad, *Dose translation from animal to human studies revisited*. Faseb J, 2008. 22(3): p. 659-61.
113. Prouillet, C., et al., *Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway*. Biochem Pharmacol, 2004. 67(7): p. 1307-13.
114. Rawat, P., et al., *Ulmosides A and B: flavonoid 6-C-glycosides from Ulmus wallichiana, stimulating osteoblast differentiation assessed by alkaline phosphatase*. Bioorg Med Chem Lett, 2009. 19(16): p. 4684-7.
115. Sanyal, S., et al., *Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis*. Proc Natl Acad Sci U S A, 2007. 104(40): p. 15665-70.
116. Bhargavan, B., et al., *Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling*. J Cell Biochem, 2009. 108(2): p. 388-99.

117. Ishizuya, T., et al., Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. *J Clin Invest*, 1997. 99(12): p. 2961-70.
118. Siddiqui, J.A., et al., 8,8''-Biapigeninyl stimulates osteoblast functions and inhibits osteoclast and adipocyte functions: Osteoprotective action of 8,8''-biapigeninyl in ovariectomized mice. *Mol Cell Endocrinol*. 323(2): p. 256-67.
119. Narayana Murthy, P.S., et al., Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression. *J Steroid Biochem Mol Biol*, 2006. 100(4-5): p. 117-28.
120. Wani, M.R., et al., Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. *Endocrinology*, 1999. 140(4): p. 1927-35.
121. Gautam, A.K., et al., Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. *J Nutr Biochem*.
122. Wattel, A., et al., Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. *Biochem Pharmacol*, 2003. 65(1): p. 35-42.
123. Oesch-Bartlomowicz, B., et al., Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. *Proc Natl Acad Sci U S A*, 2005. 102(26): p. 9218-23.
124. Nakao, Y., et al., Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. *Bone*, 2009. 44(5): p. 872-7.
125. Ahlstrom, M. and C. Lamberg-Allardt, Rapid protein kinase A--mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. *J Bone Miner Res*, 1997. 12(2): p. 172-8.
126. Sabbieti, M.G., et al., Endogenous FGF-2 is critically important in PTH anabolic effects on bone. *J Cell Physiol*, 2009. 219(1): p. 143-51.
127. Branca, F., Dietary phyto-oestrogens and bone health. *Proc Nutr Soc*, 2003. 62(4): p. 877-87.
128. Shen, C.L., et al., Green tea polyphenols mitigate deterioration of bone microarchitecture in middle-aged female rats. *Bone*, 2009. 44(4): p. 684-90.
129. Shen, C.L., et al., Protective effect of green tea polyphenols on bone loss in middle-aged female rats. *Osteoporos Int*, 2008. 19(7): p. 979-90.
130. Boots, A.W., G.R. Haenen, and A. Bast, Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol*, 2008. 585(2-3): p. 325-37.
131. Tsuji, M., et al., Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. *J Bone Miner Metab*, 2009. 27(6): p. 673-81.
132. Horcajada-Molteni, M.N., et al., Rutin inhibits ovariectomy-induced osteopenia in rats. *J Bone Miner Res*, 2000. 15(11): p. 2251-8.
133. Sharan, K., et al., Extract and fraction from *Ulmus wallichiana* Planchon promote peak bone achievement and have a nonestrogenic osteoprotective effect. *Menopause*. 17(2): p. 393-402.
134. Littlefield, B.A., et al., A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. *Endocrinology*, 1990. 127(6): p. 2757-62.

135. Tanaka, K., et al., *Deficiency of vitamin A delays bone healing process in association with reduced BMP2 expression after drill-hole injury in mice*. *Bone*. 47(6): p. 1006-12.
136. Nagashima, M., et al., *Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur*. *Bone*, 2005. 36(3): p. 502-11.
137. Tanaka, M., et al., *Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats*. *Bone*, 2004. 34(6): p. 940-8.
138. Uchida, S., et al., *Transient expression of activin betaA mRNA on osteoprogenitor cells in rat bone regeneration after drill-hole injury*. *Bone*, 2000. 27(1): p. 81-90.
139. Sharan, K., et al., *A novel flavonoid, 6-C-beta-d-glucopyranosyl-(2S,3S)-(+)-3',4',5,7-tetrahydroxyflavanone, isolated from Ulmus wallichiana Planchon mitigates ovariectomy-induced osteoporosis in rats*. *Menopause*. 17(3): p. 577-86.
140. Sato, M., G.Q. Zeng, and C.H. Turner, *Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats*. *Endocrinology*, 1997. 138(10): p. 4330-7.
141. Lane, N.E., et al., *Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats*. *J Bone Miner Res*, 1995. 10(10): p. 1470-7.
142. Siddiqui, J.A., et al., *Quercetin-6-C-beta-d-glucopyranoside isolated from Ulmus wallichiana planchon is more potent than quercetin in inhibiting osteoclastogenesis and mitigating ovariectomy-induced bone loss in rats*. *Menopause*.
143. Hildebrand, T. and P. Rueggsegger, *Quantification of Bone Microarchitecture with the Structure Model Index*. *Comput Methods Biomech Biomed Engin*, 1997. 1(1): p. 15-23.
144. Holinka, C.F., et al., *Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line)*. *Cancer Res*, 1986. 46(6): p. 2771-4.
145. Liu, J., et al., *Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms*. *J Agric Food Chem*, 2001. 49(5): p. 2472-9.
146. Theintz, G., et al., *Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects*. *J Clin Endocrinol Metab*, 1992. 75(4): p. 1060-5.
147. Fournier, P.E., et al., *Asynchrony between the rates of standing height gain and bone mass accumulation during puberty*. *Osteoporos Int*, 1997. 7(6): p. 525-32.
148. Yakar, S., et al., *Circulating levels of IGF-1 directly regulate bone growth and density*. *J Clin Invest*, 2002. 110(6): p. 771-81.
149. Bass, S.L., *The structural adaptations of cortical bone to loading during different stages of maturation*. *J Musculoskelet Neuronal Interact*, 2003. 3(4): p. 345-7; discussion 356.
150. Legrand, E., et al., *Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis*. *J Bone Miner Res*, 2000. 15(1): p. 13-9.
151. Lane, N.E., et al., *The effects of synthetic conjugated estrogens, a (cenestin) on trabecular bone structure and strength in the ovariectomized rat model*. *Osteoporos Int*, 2002. 13(10): p. 816-23.
152. Brouwers, J.E., et al., *Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT*. *Osteoporos Int*, 2009. 20(11): p. 1823-35.



153. Sliwinski, L., et al., *Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats*. *Pol J Pharmacol*, 2004. 56(6): p. 817-24.
  154. Sass, D.A., et al., *Alendronate prevents cyclosporin A-induced osteopenia in the rat*. *Bone*, 1997. 21(1): p. 65-70.
  155. Toolan, B.C., et al., *Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats*. *J Bone Miner Res*, 1992. 7(12): p. 1399-406.
-